Phase 4 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 50 years of age or older
- You have been diagnosed with active wet age-related macular degeneration (AMD) in one eye, confirmed by specific eye imaging tests
- Your vision in the eye being studied is at least 20/200 (a basic level of vision, not complete blindness)
- You do not have significant scarring or a large area of damaged tissue affecting the central part of your retina
- You are willing and able to attend all required study visits and follow study procedures
- You are able to sign a consent form agreeing to take part
Who may not be able to join:
- You have a known allergy or sensitivity to fluorescein dye, or to the medications ranibizumab, aflibercept, or brolucizumab, or to certain ingredients used in these medicines
- You have had any eye surgery in the study eye within the past 3 months
- You have a history of a specific type of fluid buildup in the eye after cataract surgery (confirm with trial site)
- You have had certain types of eye surgery — such as glaucoma drainage surgery, cornea transplant, or cataract removal — within the past 6 months, or experienced serious post-surgical complications in the past 12 months in the study eye
- You have uncontrolled glaucoma (high eye pressure that does not respond to medication) or severe damage to the optic nerve in the study eye
- You are missing the natural lens of the study eye and have no replacement (confirm with trial site)
- You have a specific type of tear or damage in the layer behind your retina affecting the central area of the study eye
- You have another eye condition in the study eye that the doctor believes will likely need medical or surgical treatment during the 12-month study
- You have active inflammation inside the study eye
- You have an active or suspected infection in or around the study eye
- You have bleeding in the gel of the study eye, or a history of a detached retina or a hole in the central part of your retina
- You currently have abnormal blood vessel growth in the iris, bleeding in the eye gel, or a type of retinal detachment caused by pulling or tension
- You have signs of an active infectious eye condition (such as an eyelid, cornea, or eye surface infection) in either eye
- You have any other eye condition in the study eye that the doctor believes could interfere with the treatment or require surgery during the study
- You have significant cloudiness, scarring, or damage to the cornea (the clear front of the eye) that affects your vision
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stefan Sacu, MD, Medical University of Vienna, Dept. of Ophthalmology and Optometry
Phone: +43 1 40400
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of injections
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.